医学
肝细胞癌
恶性肿瘤
肿瘤科
生物标志物
内科学
临床试验
癌症
重症监护医学
生物化学
化学
作者
Federico Piñero,Melisa Dirchwolf,Mário Pessôa
出处
期刊:Cells
[MDPI AG]
日期:2020-06-01
卷期号:9 (6): 1370-1370
被引量:258
摘要
Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and treatment strategies to improve the prognosis of this malignancy. The identification of useful biomarkers for surveillance and early HCC diagnosis is still deficient, with available serum biomarkers showing low sensitivity and heterogeneous specificity despite different cut-off points, even when assessed longitudinally, or with a combination of serum biomarkers. In contrast, HCC biomarkers used for prognostic (when associated with clinical outcomes) or predictive purposes (when associated with treatment response) may have an increased clinical role in the near future. Furthermore, some serum biomarkers are already implicated as a treatment selection tool, whether to provide access to certain therapies or to assess clinical benefit after treatment. In the present review we will discuss the clinical utility and foreseen future of HCC biomarkers implicated in surveillance, diagnosis, prognosis, and post-treatment assessment.
科研通智能强力驱动
Strongly Powered by AbleSci AI